AI Article Synopsis
Article Abstract
Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This article highlights the preliminary results of recent studies involving chemohormonal therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-003-0114-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The CHAARTED study showed that adding docetaxel (Doc) to androgen deprivation therapy (ADT) in men initiating treatment for metastatic hormone-sensitive prostate cancer (mHSPC) prolongs survival, particularly in high-volume disease. Androgens drive both mHSPC and metastatic castration-resistant prostate cancer (mCRPC). Lower nadir serum testosterone concentrations are associated with better outcomes in men treated with ADT for biochemical relapse, while higher androgens at mCRPC are associated with better prognosis and increased benefit from abiraterone.
View Article and Find Full Text PDFEfficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).
Int Urol Nephrol
November 2024
Department of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagito, Gifu, 501-1194, Japan.
Article Synopsis
- - The study aimed to compare the effectiveness and safety of neoadjuvant chemohormonal therapy (NCHT) versus radical prostatectomy (RP) alone in patients with high-risk prostate cancer undergoing robot-assisted surgery.
- - Data from 1,023 patients were analyzed, with results showing that those who received NCHT had a lower rate of biochemical recurrence (15.8% vs. 29.5%) and better pathology outcomes compared to the RP-only group.
- - The findings indicate that NCHT could be a beneficial pre-surgery treatment for high-risk prostate cancer, improving outcomes without significant safety concerns, although some adverse events were noted.
Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
Int J Urol
December 2024
Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
Article Synopsis
- The study aimed to assess the safety and effectiveness of neoadjuvant treatment with degarelix acetate and low-dose estramustine phosphate in men with high-/very high-risk prostate cancer before surgery.
- A total of 187 patients participated, with 140 undergoing surgery after receiving 6 months of the treatment, highlighting adverse events, surgical outcomes, and rates of biochemical recurrence.
- Results showed that patients with very high-risk status and those who reduced the dose of estramustine phosphate had lower rates of biochemical recurrence, indicating that maintaining dose compliance may impact survival outcomes in this group.
Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.
Transl Cancer Res
July 2024
Department of Urology, Graduate School of Medicine, Gifu University, Yanagido, Gifu, Japan.
Background And Objective: Prostate cancer (PCa) is the most common cancer in men. High-risk PCa is associated with an increased risk of PCa-related death. The combined use of androgen deprivation therapy (ADT) is essential to improve oncological outcomes in patients with high-risk PCa, and relatively long-term ADT administration is preferred when radiotherapy is performed.
View Article and Find Full Text PDFIntensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.
Adv Oncol
May 2024
Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!